People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kv Pharmaceutical Co /De/ | — | Pharmaceuticals | Series D+ | $526.0M | $9.2B | 2013 |
Jonathan J Siegel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan J Siegel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert E. Baldini | 1 | 2 |
| Ana I. Stancic | 1 | 2 |
| Mark A. Dow | 1 | 1 |
| Gregory S. Bentley | 1 | 1 |
| David S. Hermelin | 1 | 1 |
| Joseph D. Lehrer | 1 | 1 |
| David D. Sidransky | 1 | 1 |
| Gregory J. Divis, Jr. | 1 | 1 |
| Joe J McGinnis | 1 | 1 |
| Patrick J Christmas | 1 | 1 |
| Steve J Nielson | 1 | 1 |
| Eric J Haron | 1 | 1 |
| Gregory J Divis | 1 | 1 |
| Thomas S. McHugh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.